Applications of patient-derived tumor xenograft models and tumor organoids
GJ Yoshida - Journal of hematology & oncology, 2020 - Springer
Patient-derived tumor xenografts (PDXs), in which tumor fragments surgically dissected from
cancer patients are directly transplanted into immunodeficient mice, have emerged as a …
cancer patients are directly transplanted into immunodeficient mice, have emerged as a …
Immuno-oncology: emerging targets and combination therapies
HT Marshall, MBA Djamgoz - Frontiers in oncology, 2018 - frontiersin.org
Host immunity recognizes and eliminates most early tumor cells, yet immunological
checkpoints, exemplified by CTLA-4, PD-1, and PD-L1, pose a significant obstacle to …
checkpoints, exemplified by CTLA-4, PD-1, and PD-L1, pose a significant obstacle to …
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
B-cell lymphoma extra large (BCL-XL) is a well-validated cancer target. However, the on-
target and dose-limiting thrombocytopenia limits the use of BCL-XL inhibitors, such as …
target and dose-limiting thrombocytopenia limits the use of BCL-XL inhibitors, such as …
Application of highly immunocompromised mice for the establishment of patient-derived xenograft (PDX) models
S Okada, K Vaeteewoottacharn, R Kariya - Cells, 2019 - mdpi.com
Patient-derived xenograft (PDX) models are created by engraftment of patient tumor tissues
into immunocompetent mice. Since a PDX model retains the characteristics of the primary …
into immunocompetent mice. Since a PDX model retains the characteristics of the primary …
Mouse models of metastasis: progress and prospects
L Gómez-Cuadrado, N Tracey, R Ma… - Disease models & …, 2017 - journals.biologists.com
Metastasis is the spread of cancer cells from a primary tumor to distant sites within the body
to establish secondary tumors. Although this is an inefficient process, the consequences are …
to establish secondary tumors. Although this is an inefficient process, the consequences are …
[HTML][HTML] Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer
P Nowak-Sliwinska, L Scapozza, AR i Altaba - Biochimica et Biophysica …, 2019 - Elsevier
The strategy of using existing drugs originally developed for one disease to treat other
indications has found success across medical fields. Such drug repurposing promises faster …
indications has found success across medical fields. Such drug repurposing promises faster …
Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities
M Porru, L Pompili, C Caruso, A Biroccio… - Journal of Experimental & …, 2018 - Springer
Developing drugs that target KRAS, the most frequently mutated oncogene in cancer, has
not been successful despite much concerted efforts dedicated towards it in the last thirty …
not been successful despite much concerted efforts dedicated towards it in the last thirty …
[HTML][HTML] Translating complexity and heterogeneity of pancreatic tumor: 3D in vitro to in vivo models
MA Heinrich, AMRH Mostafa, JP Morton… - Advanced drug delivery …, 2021 - Elsevier
Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive type of cancer with
an overall survival rate of less than 7-8%, emphasizing the need for novel effective …
an overall survival rate of less than 7-8%, emphasizing the need for novel effective …
[HTML][HTML] Testicular cancer: Determinants of cisplatin sensitivity and novel therapeutic opportunities
G de Vries, X Rosas-Plaza, MATM van Vugt… - Cancer Treatment …, 2020 - Elsevier
Testicular cancer (TC) is the most common solid tumor among men aged between 15 and
40 years. TCs are highly aneuploid and the 12p isochromosome is the most frequent …
40 years. TCs are highly aneuploid and the 12p isochromosome is the most frequent …
Ex Vivo Tumor Culture Systems for Functional Drug Testing and Therapy Response Prediction
TG Meijer, KAT Naipal, A Jager, DC van Gent - Future science OA, 2017 - Taylor & Francis
Optimal patient stratification is of utmost importance in the era of personalized medicine.
Prediction of individual treatment responses by functional ex vivo assays requires model …
Prediction of individual treatment responses by functional ex vivo assays requires model …